In the pharmaceutical industry, corporate executive changes have been very frequent, with more than 200 pharmaceutical executives changing
in 2022.
It is worth noting that at the beginning of 2023, after Dr.
Jiang Ningjun, the former founding CEO of CStone Pharmaceuticals, officially announced that he had joined Hengrui Pharmaceutical, many pharmaceutical companies such as Zai Lab, GSK, and BeiGene have also announced important personnel appointments
.
BMS announces intercontinental leadership team changes
On January 4, Bristol-Myers Squibb officially announced changes to the Intercontinental leadership team to employees, and effective January 1, 2023, Chen Siyuan was promoted to Vice President and General Manager
of China and Asia Regional Markets.
Previously, Chen Siyuan was President of Bristol-Myers Squibb China, and after this promotion, he will be responsible for the Asian regional market
including Taiwan, South Korea and Southeast Asia, in addition to the Chinese mainland and Hong Kong regions.
It is understood that Chen Siyuan joined BMS on December 2, 2019 as the general manager
of Chinese mainland and Hong Kong.
Siyuan Chen has a diverse professional background and joined Novartis
in 2009.
He then joined GSK in 2015 and served as Vice President of ViiV Healthcare, Head of Business Asia Pacific, Head of GSK's China Specialty Pharmaceuticals Business Unit and Head of GSK's Respiratory and HIV Business Unit
.
Xu Ding, Vice President and Head of Respiratory Business at GSK China, stepped down
On 3 January, GSK China announced to employees that Xu Ding, Vice President and Head of Respiratory Business at GSK China, has decided to step down and take over the role by Yu Jinyi, effective
4 January 2023.
At the same time, Yu Jinyi will become a member of the GSK China management team, reporting directly to Qi Xin
, General Manager of GSK China.
In addition, GSK China announced another personnel change, with Nigel Huscroft, head of product planning, completing his tenure in China and Ji Cheng, head of strategy and operations, who will also serve as head of product planning on an interim basis
.
Notably, GSK has announced a series of executive changes
following the completion of the spin-off of Haleon, a consumer business.
For example, on October 25, 2022, a number of foreign media reported that Roger Connor, president of GSK Vaccines and Global Health, is about to leave
.
In September, GSK appointed Julie Brown, former CFO and operating officer of luxury brand Burberry, as the company's CFO, who will join GSK on 1 April 2023 for a one-month transition with the current CFO and will officially take over as CFO and executive director
of the board on 1 May 2023.
In January, it was also reported that GSK Chief Scientific Officer (CSO) Hal Barron would leave in August and be replaced by Tony Wood, senior vice president of medical science and technology
.
Zai Lab's R&D team welcomes the big coffee again
On the evening of January 3, Zai Lab announced the appointment of Dr.
Rafael G.
Amado as President, Global Head of Oncology R&D, effective
December 30, 2022.
Dr.
Amado will report to Dr.
Ying Du and will be a core member of
the Company's Management Committee.
He will be responsible for leading and managing the company's global oncology research and development efforts
.
Prior to joining Zai Lab, Dr.
Amado joined Allogene Therapeutics, Inc.
in September 2019 as its Executive Vice President, Head of Research and Development, and Chief Medical Officer
, according to public information.
Prior to joining Allogene, Dr.
Amado served as Chief Medical Officer of Adaptimmune, LLC from March 2015 to July 2018 and as its President of Research and Development and Chief Medical Officer
from August 2018 to July 2019.
Wu Zefa officially became President of Organon China
On January 3, Organon China announced that Mr.
Zafer Unluer has officially assumed the position
of President of Organon China.
As a member of Organon's global commercial leadership team, Wu Zefa will lead Organon's China team to drive the rapid development
of China's business.
It is understood that Wu Zefa has an excellent global vision and more than 20 years of rich business and leadership experience
.
Prior to joining Organon, he served as Head of Strategic Account Management at Merck China and Vice President of Merck China's Diabetes Division from 2018 to 2021, where he successfully led the team to achieve rapid growth
in the Chinese market.
BeiGene announces the appointment of Senior Director of National Key Accounts
On January 3, BeiGene announced to employees that with immediate effect, Jiangan Fu joined BeiGene as Senior Director of National Key Accounts, reporting directly to Yvonne Huang
, BeiGene's National Head of Commercial Access.
After taking office, Fu Jiangan will lead the team to continue to promote the strategic cooperative relationship between the company and key hospitals in China, while achieving the goals of
product access, safe operation and scientific research cooperation.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
